摘要
目的探讨放射性125I粒子植入联合吉西他滨治疗进展期胰腺癌的临床价值。方法2001年8月~2006年9月,64例局部进展期胰腺癌患者随机分成两组:A组32例(125I粒子+吉西他滨),B组32例(吉西他滨),分析放射性125I粒子永久植入联合吉西他滨治疗局部进展期胰腺癌的疗效,毒副反应及生存率。结果A,B两组CR+PR+MR+SD分别为81.25%(26/32),71.88%(23/32),两组比较差异有显著性(P<0.05)。两组毒性反应率和并发症发生率基本没有差异(P>0.05)。术后6个月和12个月生存率A组为75.0%,37.5%,明显高于B组的40.0%,12.5%(P<0.05)。结论放射性125I粒子植入联合吉西他滨化疗对进展期胰腺癌能提高患者生存率,是一种安全有效的治疗手段。
[Objective] To explore the significance of implanted ^125I radioactive particles into tumor combined with gemcitabine to treat extended local pancreas cancer. [Method] 64 patients treated for locally advanced pancreatic cancer were collected and randomized into two group: group A- ^125I+ gemcitabine 32 patints and B-gemcitabine 32 patints. Cure results, complication and survival rate of 64 cases extended local pancreas were analyzed prespectively. [Result] CR+PR+MR+SD of group A was 81.25% (26/32), and the difference between two groups was statistical significance (P 〈0.05). The rate of complicatiom of group A was higher than that of group B without statisileal significance (P 〉0.05). Survival rate of 6 and 12 months in group A (75%, 37.5%) was higher than that in group B (40%, 12.5%) (P 〈0.05). [Conclusion] Implanted ^125I radioactive particles into tumor combined with gemcitabine to treat extended local pancreas cancer can improve survival rate. It is a safe and effective method.
出处
《中国医学工程》
2007年第1期87-89,92,共4页
China Medical Engineering